Table 1.

Characteristics of the study sample

CharacteristicKidney Transplant Recipients, n (%)
PKD (n=10,166)No PKD (n=107,339)
Men5656 (55.6)64,327 (59.9)
Age at transplantation
 0–17 yr265 (2.6)6621 (6.2)
 18−34 yr435 (4.3)23,758 (22.1)
 35−49 yr3672 (36.1)34,707 (32.3)
 50−64 yr4896 (48.2)32,515 (30.3)
 ≥ 65 yr898 (8.8)9738 (9.1)
Race/ethnicity
 Non-Hispanic white7953 (78.2)55,461 (51.7)
 Non-Hispanic black846 (8.3)24,965 (23.3)
 Hispanic1049 (10.3)19,381 (18.1)
 Asian/Pacific Islander318 (3.1)7532 (7.0)
Donor type
 Deceased6685 (65.8)68,743 (64.0)
 Living3481 (34.2)38,596 (36.0)
Kidney transplant number
 First9541 (93.9)97,237 (90.6)
 Second588 (5.8)9342 (8.7)
 Third or higher37 (0.4)760 (0.7)
Calendar year of transplant
 1987–19941812 (17.8)20,541 (19.1)
 1995–19992549 (25.1)27,465 (25.6)
 2000–20043341 (32.9)34,218 (31.9)
 2005–20092464 (24.2)25,115 (23.4)
Initial dialysis duration
 0−5 mo3043 (29.9)20,113 (18.7)
 6−11 mo2918 (28.7)33,587 (31.3)
 12−23 mo2047 (20.1)24,903 (23.2)
 ≥24 mo1453 (14.3)21,863 (20.4)
Unknown705 (6.9)6873 (6.4)
Maintenance therapy with CNI
 Cyclosporine4643 (45.7)49,110 (45.8)
 Tacrolimus4417 (43.5)46,178 (43.0)
 Both37 (0.4)500 (0.5)
 Neither1069 (10.5)11,551 (10.8)
  • CNI, calcineurin inhibitor.